A
The startup has developed a drug platform that identifies specific antibodies linked to abnormal heart rhythms in conditions such as arrhythmogenic right ventricular cardiomyopathy and post-COVID arrhythmias. This technology enables targeted treatment strategies, improving patient outcomes and promoting longer, healthier lives.
Boston, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a drug platform that identifies specific antibodies linked to abnormal heart rhythms in conditions such as arrhythmogenic right ventricular cardiomyopathy and post-COVID arrhythmias. This technology enables targeted treatment strategies, improving patient outcomes and promoting longer, healthier lives.